Entity

Time filter

Source Type


Abril-Ulloa V.,Rovira i Virgili University | Abril-Ulloa V.,University of Cuenca | Flores-Mateo G.,Institute Universitari dInvestigacio en Atencio Primaria Jordi Gol | Flores-Mateo G.,CIBER ISCIII | And 6 more authors.
BMC Public Health | Year: 2014

Background: Elevated ferritin levels have been associated with single cardiovascular risk factors but the relationship to the presence of metabolic syndrome is inconclusive.The aim of this systematic review and meta-analysis of published observational studies was to estimate the association between serum ferritin levels and metabolic syndrome in adults. Methods. The Pubmed, SCOPUS and the Cochrane Library databases were searched for epidemiological studies that assessed the association between ferritin levels and metabolic syndrome and were published before September 2013. There were no language restrictions. Two investigators independently selected eligible studies. Measures of association were pooled by using an inverse-variance weighted random-effects model. The heterogeneity among studies was examined using the I 2 index. Publication bias was evaluated using the funnel plot. Results: Twelve cross-sectional, one case-control and two prospective studies met our inclusion criteria including data from a total of 56,053 participants. The pooled odds ratio (OR) for the metabolic syndrome comparing the highest and lowest category of ferritin levels was 1.73 (95% CI: 1.54, 1.95; I2 = 75,4%). Subgroup analyses indicate that pooled OR was 1.92 (95% CI: 1.61, 2.30; I 2 = 78%) for studies adjusting for C-reactive protein (CRP), and 1.52 (95% CI:1. 36, 1.69; I2 = 41%) for studies that did not adjust for CRP (P = 0.044). This finding was remarkably robust in the sensitivity analysis. We did not find publication bias. Conclusions: The meta-analysis suggests that increased ferritin levels are independently and positively associated with the presence of the metabolic syndrome with an odds ratio higher than 1.73. © 2014Abril-Ulloa et al.; licensee BioMed Central Ltd. Source


Sagarra R.,Institute Universitari dInvestigacio en Atencio Primaria Jordi Gol | Costa B.,Institute Universitari dInvestigacio en Atencio Primaria Jordi Gol | Cabre J.J.,Institute Universitari dInvestigacio en Atencio Primaria Jordi Gol | Sola-Morales O.,Institute Dinvestigacio Sanitaria Pere Virgili Iispv | Barrio F.,Institute Universitari dInvestigacio en Atencio Primaria Jordi Gol
Revista Clinica Espanola | Year: 2014

Background and aims: Transferring the results from clinical trials on type 2 diabetes prevention is the objective of the Diabetes in Europe-Prevention using Lifestyle, Physical Activity and Nutritional intervention (DE-PLAN) project in Catalonia, whose cost-effectiveness analysis is now presented. Patients and methods: A prospective cohort study was performed in primary care involving individuals without diagnosed diabetes aged 45-75 years (n=2054) screened using the questionnaire Finnish Diabetes Risk Score (FINDRISC) and a subsequent oral glucose tolerance test. Where feasible, high-risk individuals who were identified (n=552) were allocated sequentially to standard care (n=219), a group-based (n=230) or an individual-level (n=103) intensive (structured programme of six hours using specific teaching techniques) lifestyle intervention (n=333). The primary outcome was the development of diabetes (WHO). We evaluated the cost of resources used with comparison of standard care and the intervention groups in terms of effectiveness and quality of life (15D questionnaire). Results: After 4.2-year median follow-up, the cumulative incidences were 18.3% (14.3-22.9%) in the intensive intervention group and 28.8% (22.9-35.3%) in the standard care group (36.5% relative-risk-reduction). The corresponding 4-year HR was 0.64 (0.47-0.87; P<.004). The incremental cost induced by intensive intervention compared with the standard was 106€ per participant in the individual level and 10€ in the group-based intervention representing 746€ and 108€ per averted case of diabetes, respectively. The estimated incremental cost-utility ratio was 3243€ per quality-adjusted life-years gained. Conclusion: The intensive lifestyle intervention delayed the development of diabetes and was efficient in economic analysis. © 2013 Elsevier España, S.L. All rights reserved. Source


Gentille-Lorente D.,Institute Dinvestigacio Sanitaria Pere Virgili Iispv | Salvado-Usach T.,Institute Dinvestigacio Sanitaria Pere Virgili Iispv
Archivos de Cardiologia de Mexico | Year: 2016

Objective: Sigmoid septum and hypertrophic cardiomyopathy presenting with left ventricular hypertrophy and, although they appear to be different entities, often involve problems in the differential diagnosis. This study was carried out to assess the prevalence and characteristics of the echocardiographic sigmoid septum and its differential findings regarding hypertrophic cardiomyopathy. Methods: Descriptive, observational and prospective study. A total of 1,770 patients were studied by echocardiography. Sigmoid septum (focal and isolated hypertrophy of the basal interventricular septum ≥ 13 mm in men and ≥ 12 mm in women, exceeding ≥ 50% of the median septum thickness) was classified as «Type 1» (≤ 14 mm) and «Type 2» (≥ 15 mm). Results: There were 59 cases of sigmoid septum (prevalence of 3.3%): 26 (1.5%) patients with type 1 (50% male) and 33 (1.9%) patients with type 2 (72.7% male); there were 25 (1.4%) cases of hypertrophic cardiomyopathy (76% male). The group with type 2 sigmoid septum differed from hypertrophic cardiomyopathy in: was older (73 ± 10.5 years; P < .0001), with more hypertension (84.8%; P < .0001), lower glomerular filtering (73.3 ± 21.4 ml/min; P = .007), lower repolarization abnormalities (18.2%; P = .004) and Cornell index (in men, 22.2 ± 11 mm; P = .041), more diastolic dysfunction (75%; P = .0089) and in ventricular morphology and fibrosis location in magnetic resonance. Conclusion: Regarding the hypertrophic cardiomyopathy, patients with type 2 sigmoid septum are older and generally hypertensive; otherwise, often they have no clear differences in their clinical, electrocardiographic or echocardiographic characteristics. Therefore, cardiac resonance is helpful in the differential diagnosis. © 2016 Instituto Nacional de Cardiología Ignacio Chávez. Publicado por Masson Doyma México S.A. Source


Calavia R.,Rovira i Virgili University | Annanouch F.E.,Rovira i Virgili University | Correig X.,Rovira i Virgili University | Correig X.,Institute Dinvestigacio Sanitaria Pere Virgili Iispv | And 2 more authors.
Journal of Proteomics | Year: 2012

Mass spectrometry-based metabolomics provides a new approach to interrogate mechanistic biochemistry related to natural processes such as health and disease. Physiological and pathological conditions, however, are characterized not only by the identities and concentrations of metabolites present, but also by the location of metabolites within a tissue. Unfortunately, most relevant MS platforms in metabolomics can only measure samples in solution, therefore metabolites are typically extracted by tissue homogenization. Recent developments of imaging-MS technologies, however, have allowed particular metabolites to be spatially localized within biological tissues. In this context, Nanostructure-Initiator Mass Spectrometry (NIMS), a matrix-free technique for surface-based analysis, has proven an alternative approach for tissue imaging of metabolites. Here we review the basic principles of NIMS for tissue imaging and show applications that can complement LC/MS and GC/MS-based metabolomic studies investigating the mechanisms of fundamental biological processes. In addition, the new surface modifications and nanostructured materials herein presented demonstrate the versatility of NIMS surface to expand the range of detectable metabolites.This article is part of a Special Issue entitled: Imaging Mass Spectrometry: A User's Guide to a New Technique for Biological and Biomedical Research. © 2012 Elsevier B.V. Source


Aranda N.,Institute Dinvestigacio Sanitaria Pere Virgili Iispv | Fernandez-Cao J.C.,Institute Dinvestigacio Sanitaria Pere Virgili Iispv | Tous M.,Institute Dinvestigacio Sanitaria Pere Virgili Iispv | Arija V.,Institute Dinvestigacio Sanitaria Pere Virgili Iispv | Arija V.,Institute Universitari dInvestigacio en Atencio Primaria Jordi Gol
European Journal of Clinical Investigation | Year: 2016

Background: Many chronic diseases are adversely affected by elevated iron levels. It has been speculated that this relationship is mediated by increased oxidative stress, due to the ability of iron to generate reactive oxygen species. The aim of this study was to assess the relationship between elevated iron levels and lipid peroxidation in Caucasian adults residing in the north-eastern Mediterranean region of Spain. Materials and methods: This cross-sectional case-control study included 300 subjects: 150 adults displaying elevated iron levels (cases) selected from a representative sample of our general population and 150 age- and sex-matched adults exhibiting normal iron levels (controls). Dietary assessment (3-day food records), iron biomarkers (serum iron, ferritin and transferrin saturation) and lipid profile were determined. Elevated iron levels were defined by high serum ferritin (SF>110 μg/L in women and>200 μg/L in men) and/or transferrin saturation (TS)>45%. Oxidized low-density lipoprotein (oxLDL) plasma levels were measured, and oxLDL/LDL-cholesterol ratio was calculated to estimate lipid peroxidation. Multiple linear regression (MLR) models were applied. Results: Individuals with elevated serum iron levels showed increased oxLDL/LDL ratio, but not oxLDL levels, compared to control subjects (20·92 ± 4·89 U/mmol vs. 19·72 ± 3·573 U/mmol, P = 0·028). These results were further confirmed by the regression models adjusted for demographic characteristics, diet, lipid profile and inflammation. Importantly, higher serum levels of triglycerides, LDL-cholesterol and lower intake of Vitamin E increased lipid peroxidation. Conclusions: In our general population, we have observed that higher circulating levels of iron, measured by serum ferritin and/or TS, increased lipid peroxidation (measured by oxLDL/LDL ratio). © 2016 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd. Source

Discover hidden collaborations